TrialJournal of the American Society of Nephrology : JASN2014

The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.

Dick de Zeeuw et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.